Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the
tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) …

Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic
lymphocytic choriomeningitis virus infection. Here we examine the underlying basis for this …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …